TICKERNERD
Menu
BBLGBBLGHealthcare · Biotechnology

BBLG Stock Forecast: Bone Biologics Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.61
+1.01% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.1M
Ticker Nerd rank
23 / 100
Median analyst target
$12
Analysts covering
0
Total return, dividends reinvested
1W
−6.7%
1M
−44.9%
YTD
−57.9%
1Y
−71.8%
From 52W high
−78.6%
From 52W low
+1.0%
$0.61
$2.85
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BBLG stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bone Biologics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
23 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
100
Growth
67
Accruals
51
Revisions
39
Volatility
34
Issuance
33
Quality
27
Momentum
3
Value
2

Size (100): Smaller than most of the companies we track.

Value (2): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BBLG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BBLG, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26BBLGHigh $12Median $12Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Apr 2023EF HuttonReiteratesBuy$2.25
3 Apr 2023EF HuttonReiteratesBuy$2.25
18 Oct 2022EF HuttonInitiatesBuy$2.25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BBLG appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

BBLG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Bone Biologics Corp. (BBLG) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.1×

Cheaper than 73% of US stocks

Price / sales
—
Price / book
0.3×

Cheaper than 89% of US stocks

EV / EBITDA
0.7×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−55.0%

Higher than 20% of US stocks

Return on assets
−33.5%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BBLG vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BBLGBone Biologics Corp.$1.1M
23
DCOYDecoy Therapeutics, Inc.$2.1M
12
HELPCybin, Inc.$1.4M
41
SLXNSilexion Therapeutics Corp.$2.2M
53
CDTCDT Equity, Inc.$2.3M
15
OGENOragenics, Inc.$2.3M
10
VRAXVirax Biolabs Group Ltd.$2.5M
13

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Bone Biologics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BBLG news & analysis

Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1

GlobeNewsWire · 12 Aug 2026positive

Bone Biologics Corporation announced that the validated shelf life of its rhNELL-1 protein has been extended to 32 months. According to CEO Jeff Frelick, this gives the company greater flexibility in manufacturing, storing, and distributing rhNELL-1 as it prepares for pivotal-study scale.

Why it matters — For BBLG watchers, the longer validated shelf life signals progress toward pivotal-study readiness, supporting the company's manufacturing and distribution planning for its spine-fusion orthobiologic product.

FAQ

Frequently asked questions about BBLG stock

How does Ticker Nerd's model rank BBLG?

As at 22 Aug 2026, Bone Biologics Corp. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (100 of 100).

What is the BBLG stock forecast for 2030?

No analyst covering Bone Biologics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BBLG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.

How has BBLG stock performed over the past year?

Bone Biologics Corp. returned -71.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bone Biologics Corp. do?

Bone Biologics Corporation is a medical device company specializing in bone regeneration for spinal fusion procedures. Its core technology revolves around the NELL-1 platform, featuring recombinant human NELL-1 protein that offers target-specific control over bone growth.

What is the latest news on BBLG?

The most recent item we track (GlobeNewsWire, 12 Aug 2026): "Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1". Bone Biologics Corporation announced that the validated shelf life of its rhNELL-1 protein has been extended to 32 months. According to CEO Jeff Frelick, this gives the company greater flexibility in manufacturing, storing, and distributing rhNELL-1 as it prepares for pivotal-study scale.

Company

About Bone Biologics Corp.

Bone Biologics Corporation is a medical device company specializing in bone regeneration for spinal fusion procedures. Its core technology revolves around the NELL-1 platform, featuring recombinant human NELL-1 protein that offers target-specific control over bone growth. The lead product, NB1, combines rhNELL-1 with demineralized bone matrix to serve as a bone graft in spinal fusion surgeries, particularly for degenerative disc disease and lumbar interbody fusion. This technology also applies to orthopedic surgeries, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine, addressing skeletal bone defects and related conditions. Bone Biologics Corporation targets spine surgeons and patients requiring enhanced bone healing outcomes. It holds a license agreement with the UCLA Technology Development Group for developing and commercializing NELL-1 in spinal fusion. Founded in 2004 and headquartered in Burlington, Massachusetts, the company operates within the healthcare sector's medical devices industry, focusing on orthobiologic solutions for spine fusion markets.

CEO Mr. Jeffrey Frelick · 2 employees · United States · https://www.bonebiologics.com